Cantor Fitzgerald Reiterates Overweight Rating for Kura Oncology (NASDAQ:KURA)

Kura Oncology (NASDAQ:KURA)‘s stock had its “overweight” rating reiterated by equities researchers at Cantor Fitzgerald in a report released on Monday, Benzinga reports.

Other equities analysts have also issued reports about the stock. JMP Securities reiterated a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a research note on Monday, August 12th. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, August 22nd. Wedbush reissued an “outperform” rating and issued a $37.00 price target on shares of Kura Oncology in a research report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. Finally, Stifel Nicolaus reduced their target price on Kura Oncology from $28.00 to $26.00 and set a “buy” rating for the company in a report on Friday, August 9th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, Kura Oncology has a consensus rating of “Moderate Buy” and an average price target of $30.60.

Kura Oncology Stock Up 0.9 %

Kura Oncology stock opened at $19.74 on Monday. The company has a market capitalization of $1.51 billion, a PE ratio of -9.10 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. Kura Oncology has a fifty-two week low of $7.41 and a fifty-two week high of $24.17. The firm has a 50 day moving average price of $20.28 and a 200 day moving average price of $20.66.

Kura Oncology (NASDAQ:KURA) last released its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. The company’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.53) EPS. Research analysts expect that Kura Oncology will post -2.45 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC boosted its position in shares of Kura Oncology by 29.2% during the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $82,120,000 after purchasing an additional 870,000 shares in the last quarter. BVF Inc. IL grew its position in Kura Oncology by 9.5% during the fourth quarter. BVF Inc. IL now owns 7,373,228 shares of the company’s stock worth $106,027,000 after buying an additional 642,245 shares during the period. Assenagon Asset Management S.A. grew its position in Kura Oncology by 50.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after buying an additional 577,732 shares during the period. Affinity Asset Advisors LLC increased its holdings in Kura Oncology by 281.4% in the first quarter. Affinity Asset Advisors LLC now owns 730,492 shares of the company’s stock valued at $15,581,000 after buying an additional 538,957 shares in the last quarter. Finally, Verition Fund Management LLC acquired a new stake in shares of Kura Oncology during the 4th quarter valued at approximately $6,695,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.